Anti-Aging · Reference
MOTS-c for Women: The Menopause Mouse Studies, Read Carefully
This page covers what MOTS-c is, what research has looked at in relation to women and what it has not, the considerations that matter, and how Pepti supplies it. For the general evidence, see MOTS-c benefits; for the full reference, what is MOTS-c.
Treatments mentioned
The MOTS-c research most often quoted for women comes from ovariectomised mice, a standard animal model of post-menopausal metabolic change: a 2019 study reported less fat accumulation and more brown-fat activity in treated animals, and a 2016 study reported less bone loss. Those are mouse findings. There are no randomized controlled trials of MOTS-c in humans of either sex, and the one human genetic finding linking MOTS-c to type 2 diabetes was seen in men. MOTS-c is not hormone therapy, is not a treatment for osteoporosis, and is not used in pregnancy or breastfeeding. It is a compounded prescription injection and is not FDA approved.
This page covers what MOTS-c is, what research has looked at in relation to women and what it has not, the considerations that matter, and how Pepti supplies it. For the general evidence, see MOTS-c benefits; for the full reference, what is MOTS-c.
MOTS-c for Women
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Fat gain after loss of ovarian hormones | Less fat accumulation and less inflammation in white fat, ovariectomised mice (Journal of Molecular Medicine, 2019) | Animal only |
| Brown-fat activity | More brown-fat activity, same 2019 mouse study | Animal only |
| Bone loss after loss of ovarian hormones | Less bone loss on micro-CT, ovariectomised mice (Biochemical and Biophysical Research Communications, 2016) | Animal and cell only |
| Insulin sensitivity | Mouse studies (2015); a human genetic association seen in men (2021); lower levels in type 2 diabetes in a mixed group (2019) | Preclinical, with human association; no treatment trial |
| Has it been tested in women? | No human treatment trial in either sex | None |
| Menopause symptoms | Not studied | None |
| Pregnancy or breastfeeding | Not used; safety data is absent | Clear exclusion |
The honest summary: a coherent mouse story that happens to use a menopause model, and nothing yet in women.
MOTS-c for Women
What MOTS-c is, in one paragraph
MOTS-c is a 16-amino-acid peptide whose gene sits in mitochondrial DNA rather than in the cell nucleus. It was identified in a 2015 Cell Metabolism paper from a group at the University of Southern California. The described mechanism is metabolic: in cultured cells it slows the folate cycle, a molecule called AICAR builds up, and AICAR activates AMPK, the enzyme cells use as a low-fuel sensor, the same one exercise switches on. Skeletal muscle appeared to be the main target. It is not a hormone, not a growth hormone secretagogue, not a GLP-1 medication, does not work through appetite, and does not act on estrogen or the reproductive axis.
MOTS-c for Women
What research has looked at in relation to women
Why ovariectomised mice
Ovariectomy, surgical removal of the ovaries, is a standard animal model of post-menopausal metabolic change. That is why these studies are quoted for women. It is also their limit: a mouse without ovaries is a model, not a woman in perimenopause or after menopause.
Fat and brown fat: the 2019 study
A 2019 paper in the Journal of Molecular Medicine treated ovariectomised mice with MOTS-c and reported less fat accumulation and less inflammatory infiltration in white fat, and more brown-fat activity, through AMPK. Brown fat burns fuel to make heat rather than storing it, which is why the finding is quoted.
What it shows. Prevention of fat gain, in mice, after their ovaries were removed.
What it does not show. Loss of fat already there, or anything in people. There is no human trial showing weight or fat change from MOTS-c. If weight is the actual concern around menopause, semaglutide and tirzepatide have large randomized human trials with weight as the primary endpoint, and the STEP trials enrolled a majority of women; see peptides for menopause.
Bone: the 2016 study
A 2016 paper in Biochemical and Biophysical Research Communications, also in ovariectomised mice, reported less bone loss on micro-CT in treated animals, and that MOTS-c inhibited RANKL-driven formation of osteoclasts, the cells that break bone down, in an AMPK-dependent way.
What it means. This is why osteoporosis sat alongside obesity as a nominated use when the FDA's advisory committee reviewed MOTS-c in July 2026. Nomination is not evidence. There is no human bone study of MOTS-c, and it is not a treatment for osteoporosis. The fastest bone loss happens in the years around the final period, and protecting bone is a DEXA scan, calcium, vitamin D, resistance training and a medical conversation, not a peptide.
Insulin sensitivity: the human data, and who it was in
The founding 2015 work reported that MOTS-c prevented age-related and diet-induced insulin resistance in mice. Two kinds of human data sit alongside it, and neither involved giving anyone MOTS-c:
Study Who What was reported Aging, 2021 Three cohorts totalling 27,527 people An East Asian mitochondrial DNA variant that changes one amino acid in MOTS-c was associated with higher type 2 diabetes prevalence in men, particularly sedentary men Frontiers in Endocrinology, 2019 225 people in Qatar Lower serum MOTS-c in people with type 2 diabetes than in controls Journal of Investigative Medicine, 2018 Ten lean and ten obese adults Similar levels with and without obesity Archives of Endocrinology and Metabolism, 2025 85 adults Similar levels with and without obesity The genetic association was a finding in men. The observational studies do not line up neatly, and raising MOTS-c by injection has not been shown to do what naturally higher levels correlate with.
Exercise and late life
A 2021 paper in Nature Communications reported better physical performance in treated mice of every age tested, a longer healthy lifespan with intermittent treatment started late in life, and, in humans, that a bout of exercise raised the body's own MOTS-c. The human part describes what the body does after exercise, not what an injection does. None of it was reported for women separately.
The analogue trial
A modified analogue, CB4211, went through a small company-reported Phase 1 program in adults with obesity and fatty liver disease. It is a different molecule, the results were company announcements rather than a peer-reviewed publication, and the program did not advance beyond Phase 1.
MOTS-c for Women
What changes for women
Menopause is a separate conversation
MOTS-c has not been tested for hot flashes, night sweats, sleep, mood or any other menopause symptom, and it does not replace the hormones that change. If the transition is the driver, it belongs in its own conversation with your physician; Pepti does not prescribe menopausal hormone therapy. Peptides for women covers what else changes.
Pregnancy and breastfeeding
MOTS-c is not used in pregnancy or breastfeeding. There is no human safety data, no approved product to carry a label, and no human lactation data of any kind. If you become pregnant on treatment, stop and contact your physician the same day. See can you take peptides while pregnant and do peptides affect fertility.
Fatigue has findable causes
Some people describe steadier energy on MOTS-c; others notice nothing, and no study has measured energy or fatigue. In women, iron deficiency and thyroid disease are common, findable causes of fatigue and are worth checking first. See peptides for energy and fatigue.
Blood sugar
Because the described mechanism is insulin sensitivity, anything you take that lowers blood glucose belongs on your intake.
Contraception and the cycle
MOTS-c is not described as acting on the reproductive axis, and no study has looked at the cycle or hormonal contraception. List your contraception on your intake and report any change.
Sport
MOTS-c is on the World Anti-Doping Agency Prohibited List at all times as an AMPK activator, USADA has stated it is not eligible for a therapeutic use exemption, and a validated plasma test was published in 2019. If you compete in a tested sport, it is not a peptide for you.
MOTS-c for Women
What the evidence does not establish
- That MOTS-c changes fat, weight, bone or glucose in women. Those trials have not been run in anyone.
- That ovariectomised-mouse findings transfer to women after menopause.
- Any effect on menopause symptoms.
- An effect size or a timeline.
- Long-term safety over years of use.
- Efficacy for any condition as an approved treatment. MOTS-c is not an approved drug anywhere.
MOTS-c for Women
Side effects
| What is reported | When | What to do |
|---|---|---|
| Injection-site redness, mild soreness, occasional bruising | Any time | Rotate sites |
| Transient jitteriness, a faster pulse or mild light-headedness | The hour or two after a morning dose, mostly early in a course | Usually settles; tell your physician if it does not |
| A reaction that is severe, spreading, or involves difficulty breathing | Rare | Call 911, then tell your physician |
The published animal work reports MOTS-c as well tolerated. There is no human safety data from trials and no established interaction list, which is why the intake asks for every medication you take.
MOTS-c for Women
Where MOTS-c stands with the FDA
MOTS-c was removed from Category 2 of the FDA's interim 503A list on 15 April 2026. When the FDA's own reviewers assessed it for the advisory committee in July 2026, they recommended against adding it to the 503A Bulks List, citing the absence of human clinical data. On 23 July 2026 the committee voted 7 to 5, with two abstentions, to recommend adding it anyway, for the nominated uses of obesity and osteoporosis. A committee vote is a recommendation, not a decision; the FDA's final determination is pending, and MOTS-c remains legal to prescribe and dispense. Compounded MOTS-c is not FDA approved.
MOTS-c for Women
How Pepti supplies MOTS-c
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| MOTS-c | 5 mL multi-dose vial, 2 mg/mL (10 mg MOTS-c) | 0.25 mL (25 units) subcutaneously Monday through Friday mornings | $259/mo |
| PHYSIQ | 10 mg each of tesamorelin, ipamorelin, AOD-9604 and MOTS-c in 5 mL | Printed on the vial | $289/mo |
| EUPHORIA | 10 mg MOTS-c, 10 mg BPC-157, 50 mg GHK-Cu, 2 mg kisspeptin in 5 mL | Printed on the vial | $279/mo |
| SHRED | 10 mg AOD-9604, 6 mg CJC-1295, 10 mg ipamorelin, 10 mg MOTS-c in 5 mL | Printed on the vial | $279/mo |
On the MOTS-c vial, 0.25 mL at 2 mg/mL is 0.5 mg per dose (math only), 20 doses per vial, about four weeks, which is why refills run every 28 days, one vial per fill. Morning timing places the dose near the day's activity. EUPHORIA also contains kisspeptin, which acts on the reproductive axis; see kisspeptin for women. No study has tested MOTS-c in combination with anything. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The dosing detail is in MOTS-c dosage.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive ready to use with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Lot test results are at /quality/lab-results.
MOTS-c for Women
Where to get MOTS-c prescribed
MOTS-c cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications (especially anything that lowers blood glucose), pregnancy and breastfeeding status, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and side effects.
Step by step: how to get MOTS-c prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Lee C, Zeng J, Drew BG et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance · Cell Metab (2015) · PMID 25738459
- Reynolds JC, Lai RW, Woodhead JST et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis · Nat Commun (2021) · PMID 33473109
- Kim KH, Son JM, Benayoun BA et al.. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress · Cell Metab (2018) · PMID 29983246
- Zempo H, Kim SJ, Fuku N et al.. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c · Aging (Albany NY) (2021) · PMID 33468709
- Ramanjaneya M, Bettahi I, Jerobin J et al.. Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects · Front Endocrinol (Lausanne) (2019) · PMID 31214116
- Cataldo LR, Fernández-Verdejo R, Santos JL et al.. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals · J Investig Med (2018) · PMID 29593067
- Lu H, Wei M, Zhai Y et al.. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction · J Mol Med (Berl) (2019) · PMID 30725119
- Ming W, Lu G, Xin S et al.. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation · Biochem Biophys Res Commun (2016) · PMID 27237975
- Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes · Rapid Commun Mass Spectrom (2019) · PMID 30394592
- Ozkaya DY, Haymana C, Demirci I et al.. MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction · Arch Endocrinol Metab (2025) · PMID 41004666
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
MOTS-c for Women, answered.
The research quoted for women is in ovariectomised mice, a model of post-menopausal change, reporting less fat gain, more brown-fat activity and less bone loss. There is no human treatment trial in women or men, so any benefit for women is described in animals, not established in people.
In mice without ovaries, MOTS-c was reported to prevent fat gain. That is prevention of gain in a mouse model, not loss of fat in women. There is no human trial showing weight or fat change from MOTS-c, and it is not a weight-loss drug.
One 2016 study reported less bone loss in ovariectomised mice. There is no human bone study, and MOTS-c is not a treatment for osteoporosis, even though osteoporosis was a nominated use at the FDA's 2026 review.
It is not described as acting on estrogen or the reproductive axis; its described mechanism is AMPK in muscle. No study has looked at cycle or hormone effects in women.
No. It is not used in either situation because there is no safety data.
No study has measured energy or fatigue in people given MOTS-c. Some people describe steadier energy; others notice nothing. In women, iron and thyroid are worth checking first.
Mostly injection-site redness, soreness or bruising, and sometimes transient jitteriness, a faster pulse or mild light-headedness after a morning dose early in a course. Nothing in the live research suggests the profile differs for women.
No interaction has been described, but none has been studied and there is no established interaction list. List both on your intake so your physician can review them together.
Yes. It is on the WADA Prohibited List at all times as an AMPK activator, for all athletes.
At Pepti, the MOTS-c vial is $259 a month, all-in, covering medication, physician review, refill management and shipping. The blends that contain it run $279 to $289.
No. Compounded medications are not FDA approved, and MOTS-c is not an approved drug anywhere. The advisory committee's July 2026 recommendation is not a final FDA decision. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.